Analgesic requirement for Post-Operative pain control in elective 1-3 level transforaminal lumbar interbody fusion: comparison of thoracolumbar interfascial plane block with exparel to bupivacaine HCl
NCT ID NCT06350981
First seen Sep 09, 2026 · Last updated Sep 09, 2026
Summary
The goal of this clinical trail is to to compare the efficacy of thoracolumbar interfascial plane block with Exparel vs with standard of care 0.25% Bupivacaine HCl in patients undergoing 1-3 level elective transforaminal lumbar interbody fusion. The investigators hypothesize that thoracolumbar interfascial plane block with Exparel will outperform standard of care (supplemented with interfascial plane block of 0.25% Bupivacaine HCl) with regards to pain reduction, narcotic use, length of hospital stay, time to mobilization with physical therapy, narcotic usage in the hospital, and post operative pain scores.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Participants
-
About 76 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2024
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients 18 years or older, * Patients admitted to AHC for 1-3 level TLIF, * Patients who have given written informed consent, * BMI between 18-35 kg/m2, Exclusion Criteria: * Patients with known allergic reactions to standard of care analgesics, * Female patients who are pregnant * Patients with any previous lumbar spine instrumented surgery, * Chronic opioid use within 30 days prior to randomization that exceeds average ≥30 oral morphine equivalents/day, * Patients with known allergy to local anesthetics, * Patients with known or suspected to have neuromuscular disorders impairing neuromuscular blockade (e.g. myasthenia gravis).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Back pain are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Foundation for Orthopaedic Research and Education
Tampa, Florida, 33607, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Propofol vs. inhaled anesthesia: which one spares your recovery?
- Could a simple mineral calm the Body's Post-Surgery fire?
- Can a simple ointment make surgical scars heal better?
- Nanoparticle cleaning may calm pain after failed root canals in diabetic patients
- One pill before surgery may cut opioid use and improve sleep
- Can a Two-Drug anesthetic mix ease pain and cut narcotic use after heart device surgery?